NECTIN-4-redirected T cell Antigen Coupler T cells bearing CD28 show superior antitumor responses against solid tumors
Our data highlighted that NECTIN-4 TAC28-T cells may represent a promising, safe and effective cell therapy for NECTIN-4-overexpressing solid tumors.
Authors
- Peiyuan Zhang (ORCID: https://orcid.org/0000-0003-4086-3436)
- Tianlong Xu (ORCID: https://orcid.org/0009-0009-4598-0798)
- F.-W. Wang
- Qiaolin He (ORCID: https://orcid.org/0000-0002-3627-5351)
- Yue Gao (ORCID: https://orcid.org/0000-0003-0403-6783)
- Jimin Gao
- Ai Zhao (ORCID: https://orcid.org/0000-0002-1679-973X)
- Binjiao Zheng
- Ying Zhang (ORCID: https://orcid.org/0000-0003-1936-6101)
- Xin Huang (ORCID: https://orcid.org/0000-0003-3811-9480)
- Yongping Chen (ORCID: https://orcid.org/0000-0002-3721-8180)
- Qichuan Zhuge (ORCID: https://orcid.org/0000-0002-9100-8280)
- Wei Cheng (ORCID: https://orcid.org/0000-0002-0088-7209)
- Qianjin Yu
- Yi-nan Fang
- Jinhong Jiang
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fimmu.2024.1456443
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Natural Science Foundation of Guangdong Province